Table 1 Demographic characteristics of LM patients who underwent PTNB and received PTC culture
Variables | Overall (n = 68) | Success of PTC culture (n = 56) | Failure of PTC culture (n = 12) |
|---|---|---|---|
Age(y) | 70.0 ± 12.5 | 66.1 ± 13.3 | 71.5 ± 6.6 |
Gender | |||
 Male | 42(61.8%) | 32(57.1%) | 10(83.3%) |
 Female | 26(38.2%) | 24(42.9%) | 2(16.7%) |
Comorbidity | |||
 Hypertension | 28(41.2%) | 22(39.3%) | 6(50.0%) |
 Diabetes | 7(10.3%) | 7(12.5%) | 0 |
Tumor subtypes | |||
 Adenocarcinoma | 32(47.1%) | 29(51.8%) | 3(25.0%) |
 Squamous cell carcinoma | 18(26.5%) | 13(23.2%) | 5(41.7%) |
 Other subtypes of NSCLC | 7(10.3%) | 3(5.4%) | 4(33.3%) |
 SCLC | 7(10.3%) | 7(12.5%) | 0 |
 Lung metastases | 4(5.9%) | 4(7.1%) | 0 |
Tumor stage | |||
 I | 1(1.5%) | 1(1.8%) | 0 |
 II | 0 | 0 | 0 |
 III | 52(76.5%) | 45(80.4%) | 7(58.3%) |
 IV | 15(22.1%) | 10(17.9%) | 5(41.7%) |
Extrapulmonary metastases | 12(17.6%) | 8(14.3%) | 4(33.3%) |
ECOG PS | |||
 0 | 12(17.6%) | 10(17.9%) | 2(16.7%) |
 1 | 44(64.7%) | 38(67.9%) | 6(50.0%) |
 2 | 10(14.7%) | 6(10.7%) | 4(33.3%) |
 3 | 2(2.9%) | 2(3.6%) | 0 |
Treatment history | |||
 Systemic chemotherapy | 4(5.9%) | 3(5.4%) | 1(8.3%) |
 Radiotherapy | 1(1.5%) | 1(1.8%) | 0 |
 Molecular targeted therapy | 3(4.4%) | 2(3.6%) | 1(8.3%) |
 ICIs | 2(2.9%) | 1(1.8%) | 1(8.3%) |
Radiological features | |||
 Tumor diameter (cm) | 5.1 ± 2.1 | 5.0 ± 2.0 | 6.2 ± 2.2 |
 Location | |||
  Lower or middle lobe | 28(41.2%) | 25(44.6%) | 3(25.0%) |
  Upper lobe | 40(58.8%) | 31(55.4%) | 9(75.0%) |
 Intrapulmonary tumor number | |||
  1 | 60(88.2%) | 50(89.3%) | 10(83.3%) |
  ≥2 | 8(11.8%) | 6(10.7%) | 2(16.7%) |
 Necrosis over half of the tumor | |||
  Yes | 10(14.7%) | 4(7.1%) | 6(50%) |
  No | 58(85.3%) | 52(92.9%) | 6(50%) |
 Emphysema | 34(50.0%) | 24(42.9%) | 10(83.3%) |
Diameter of biopsy instruments | |||
 16 G | 31(45.6%) | 25(44.6%) | 6(50%) |
 18 G | 37(54.4%) | 31(55.4%) | 6(50%) |